nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludrocortisone—AR—scrotum—sarcoma	0.11	0.273	CbGeAlD
Fludrocortisone—Muscle atrophy—Vincristine—sarcoma	0.0268	0.0588	CcSEcCtD
Fludrocortisone—NR3C2—myometrium—sarcoma	0.015	0.0372	CbGeAlD
Fludrocortisone—NR3C2—seminal vesicle—sarcoma	0.0136	0.0336	CbGeAlD
Fludrocortisone—NR3C2—hematopoietic system—sarcoma	0.0129	0.0319	CbGeAlD
Fludrocortisone—NR3C2—connective tissue—sarcoma	0.0124	0.0307	CbGeAlD
Fludrocortisone—Skin hyperpigmentation—Thiotepa—sarcoma	0.012	0.0262	CcSEcCtD
Fludrocortisone—NR3C2—smooth muscle tissue—sarcoma	0.0114	0.0281	CbGeAlD
Fludrocortisone—AR—myometrium—sarcoma	0.0111	0.0275	CbGeAlD
Fludrocortisone—AR—seminal vesicle—sarcoma	0.01	0.0249	CbGeAlD
Fludrocortisone—NR3C2—cardiac atrium—sarcoma	0.00979	0.0242	CbGeAlD
Fludrocortisone—NR3C2—uterus—sarcoma	0.00974	0.0241	CbGeAlD
Fludrocortisone—AR—hematopoietic system—sarcoma	0.00955	0.0236	CbGeAlD
Fludrocortisone—AR—connective tissue—sarcoma	0.00919	0.0228	CbGeAlD
Fludrocortisone—NR3C2—tendon—sarcoma	0.00853	0.0211	CbGeAlD
Fludrocortisone—AR—smooth muscle tissue—sarcoma	0.00841	0.0208	CbGeAlD
Fludrocortisone—Optic neuritis—Etoposide—sarcoma	0.0083	0.0182	CcSEcCtD
Fludrocortisone—AR—skin of body—sarcoma	0.0083	0.0206	CbGeAlD
Fludrocortisone—Amenorrhoea—Thiotepa—sarcoma	0.00809	0.0178	CcSEcCtD
Fludrocortisone—NR3C1—myometrium—sarcoma	0.00805	0.0199	CbGeAlD
Fludrocortisone—Cardiomegaly—Epirubicin—sarcoma	0.00785	0.0172	CcSEcCtD
Fludrocortisone—NR3C1—embryo—sarcoma	0.00775	0.0192	CbGeAlD
Fludrocortisone—Cataract—Thiotepa—sarcoma	0.00747	0.0164	CcSEcCtD
Fludrocortisone—Petechiae—Mitoxantrone—sarcoma	0.00746	0.0164	CcSEcCtD
Fludrocortisone—NR3C1—seminal vesicle—sarcoma	0.00727	0.018	CbGeAlD
Fludrocortisone—Cardiomegaly—Doxorubicin—sarcoma	0.00726	0.0159	CcSEcCtD
Fludrocortisone—AR—cardiac atrium—sarcoma	0.00725	0.018	CbGeAlD
Fludrocortisone—AR—uterus—sarcoma	0.00721	0.0179	CbGeAlD
Fludrocortisone—NR3C2—testis—sarcoma	0.00706	0.0175	CbGeAlD
Fludrocortisone—Contusion—Mitoxantrone—sarcoma	0.00704	0.0155	CcSEcCtD
Fludrocortisone—Amenorrhoea—Mitoxantrone—sarcoma	0.00699	0.0153	CcSEcCtD
Fludrocortisone—NR3C1—hematopoietic system—sarcoma	0.00691	0.0171	CbGeAlD
Fludrocortisone—AR—FOXA1 transcription factor network—COL18A1—sarcoma	0.00688	0.0488	CbGpPWpGaD
Fludrocortisone—Fluid retention—Thiotepa—sarcoma	0.00675	0.0148	CcSEcCtD
Fludrocortisone—AR—lymphoid tissue—sarcoma	0.00672	0.0166	CbGeAlD
Fludrocortisone—NR3C2—liver—sarcoma	0.00668	0.0165	CbGeAlD
Fludrocortisone—NR3C1—connective tissue—sarcoma	0.00666	0.0165	CbGeAlD
Fludrocortisone—Oesophagitis—Thiotepa—sarcoma	0.0065	0.0143	CcSEcCtD
Fludrocortisone—Oesophagitis—Dactinomycin—sarcoma	0.00645	0.0142	CcSEcCtD
Fludrocortisone—AR—tendon—sarcoma	0.00632	0.0157	CbGeAlD
Fludrocortisone—NR3C1—smooth muscle tissue—sarcoma	0.00609	0.0151	CbGeAlD
Fludrocortisone—NR3C1—skin of body—sarcoma	0.00601	0.0149	CbGeAlD
Fludrocortisone—AR—Notch-mediated HES/HEY network—TLE1—sarcoma	0.00586	0.0416	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—sarcoma	0.00581	0.0412	CbGpPWpGaD
Fludrocortisone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—sarcoma	0.00578	0.041	CbGpPWpGaD
Fludrocortisone—Ecchymosis—Mitoxantrone—sarcoma	0.00555	0.0122	CcSEcCtD
Fludrocortisone—AR—Notch-mediated HES/HEY network—MYOD1—sarcoma	0.00549	0.039	CbGpPWpGaD
Fludrocortisone—Hypernatraemia—Epirubicin—sarcoma	0.00545	0.012	CcSEcCtD
Fludrocortisone—AR—Nongenotropic Androgen signaling—PLCG1—sarcoma	0.00542	0.0385	CbGpPWpGaD
Fludrocortisone—NR3C1—cardiac atrium—sarcoma	0.00525	0.013	CbGeAlD
Fludrocortisone—AR—testis—sarcoma	0.00523	0.013	CbGeAlD
Fludrocortisone—NR3C1—uterus—sarcoma	0.00522	0.0129	CbGeAlD
Fludrocortisone—NR3C2—lymph node—sarcoma	0.00512	0.0127	CbGeAlD
Fludrocortisone—Hypernatraemia—Doxorubicin—sarcoma	0.00504	0.0111	CcSEcCtD
Fludrocortisone—AR—liver—sarcoma	0.00495	0.0123	CbGeAlD
Fludrocortisone—Cardiac failure congestive—Mitoxantrone—sarcoma	0.00492	0.0108	CcSEcCtD
Fludrocortisone—NR3C1—lymphoid tissue—sarcoma	0.00487	0.0121	CbGeAlD
Fludrocortisone—Skin hyperpigmentation—Epirubicin—sarcoma	0.00481	0.0106	CcSEcCtD
Fludrocortisone—Oesophagitis—Etoposide—sarcoma	0.00467	0.0102	CcSEcCtD
Fludrocortisone—Optic neuritis—Epirubicin—sarcoma	0.00465	0.0102	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Etoposide—sarcoma	0.00464	0.0102	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Mitoxantrone—sarcoma	0.00461	0.0101	CcSEcCtD
Fludrocortisone—NR3C1—tendon—sarcoma	0.00458	0.0113	CbGeAlD
Fludrocortisone—Skin hyperpigmentation—Doxorubicin—sarcoma	0.00445	0.00978	CcSEcCtD
Fludrocortisone—NR3C1—bone marrow—sarcoma	0.00443	0.011	CbGeAlD
Fludrocortisone—Optic neuritis—Doxorubicin—sarcoma	0.00431	0.00946	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Etoposide—sarcoma	0.00409	0.00898	CcSEcCtD
Fludrocortisone—Muscular weakness—Vincristine—sarcoma	0.00404	0.00886	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Thiotepa—sarcoma	0.00402	0.00884	CcSEcCtD
Fludrocortisone—Dermatitis atopic—Epirubicin—sarcoma	0.00387	0.00849	CcSEcCtD
Fludrocortisone—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—sarcoma	0.00384	0.0272	CbGpPWpGaD
Fludrocortisone—Anaphylactoid reaction—Etoposide—sarcoma	0.00383	0.00841	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TLE1—sarcoma	0.00383	0.0272	CbGpPWpGaD
Fludrocortisone—AR—lymph node—sarcoma	0.00379	0.00939	CbGeAlD
Fludrocortisone—NR3C1—testis—sarcoma	0.00379	0.00939	CbGeAlD
Fludrocortisone—Sweating increased—Mitoxantrone—sarcoma	0.00375	0.00824	CcSEcCtD
Fludrocortisone—Haemoglobin—Thiotepa—sarcoma	0.00359	0.00788	CcSEcCtD
Fludrocortisone—NR3C1—liver—sarcoma	0.00358	0.00887	CbGeAlD
Fludrocortisone—Dermatitis atopic—Doxorubicin—sarcoma	0.00358	0.00786	CcSEcCtD
Fludrocortisone—Haemorrhage—Thiotepa—sarcoma	0.00357	0.00784	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.00355	0.0252	CbGpPWpGaD
Fludrocortisone—Glycosuria—Epirubicin—sarcoma	0.00353	0.00776	CcSEcCtD
Fludrocortisone—Petechiae—Epirubicin—sarcoma	0.00348	0.00764	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Mitoxantrone—sarcoma	0.00348	0.00763	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—sarcoma	0.00334	0.0237	CbGpPWpGaD
Fludrocortisone—Glycosuria—Doxorubicin—sarcoma	0.00327	0.00718	CcSEcCtD
Fludrocortisone—Amenorrhoea—Epirubicin—sarcoma	0.00326	0.00715	CcSEcCtD
Fludrocortisone—Petechiae—Doxorubicin—sarcoma	0.00322	0.00707	CcSEcCtD
Fludrocortisone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—CREB1—sarcoma	0.00313	0.0222	CbGpPWpGaD
Fludrocortisone—Sweating increased—Etoposide—sarcoma	0.00312	0.00685	CcSEcCtD
Fludrocortisone—Erythema—Thiotepa—sarcoma	0.00311	0.00683	CcSEcCtD
Fludrocortisone—Haemoglobin—Mitoxantrone—sarcoma	0.0031	0.00681	CcSEcCtD
Fludrocortisone—Erythema—Dactinomycin—sarcoma	0.00308	0.00677	CcSEcCtD
Fludrocortisone—Haemorrhage—Mitoxantrone—sarcoma	0.00308	0.00677	CcSEcCtD
Fludrocortisone—Amenorrhoea—Doxorubicin—sarcoma	0.00301	0.00662	CcSEcCtD
Fludrocortisone—AR—Nongenotropic Androgen signaling—CREB1—sarcoma	0.00279	0.0198	CbGpPWpGaD
Fludrocortisone—NR3C1—Transcription factor regulation in adipogenesis—CREB1—sarcoma	0.00278	0.0198	CbGpPWpGaD
Fludrocortisone—NR3C1—lymph node—sarcoma	0.00275	0.0068	CbGeAlD
Fludrocortisone—Fluid retention—Epirubicin—sarcoma	0.00272	0.00597	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.0027	0.0191	CbGpPWpGaD
Fludrocortisone—Convulsion—Thiotepa—sarcoma	0.00269	0.00591	CcSEcCtD
Fludrocortisone—Erythema—Mitoxantrone—sarcoma	0.00268	0.00589	CcSEcCtD
Fludrocortisone—Hypertension—Thiotepa—sarcoma	0.00268	0.00589	CcSEcCtD
Fludrocortisone—Myalgia—Thiotepa—sarcoma	0.00265	0.00581	CcSEcCtD
Fludrocortisone—Myalgia—Dactinomycin—sarcoma	0.00263	0.00577	CcSEcCtD
Fludrocortisone—Oesophagitis—Epirubicin—sarcoma	0.00262	0.00574	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Epirubicin—sarcoma	0.0026	0.00571	CcSEcCtD
Fludrocortisone—Ecchymosis—Epirubicin—sarcoma	0.00259	0.00568	CcSEcCtD
Fludrocortisone—Neoplasm—Epirubicin—sarcoma	0.00259	0.00568	CcSEcCtD
Fludrocortisone—Infection—Thiotepa—sarcoma	0.00252	0.00553	CcSEcCtD
Fludrocortisone—Oedema—Dactinomycin—sarcoma	0.00252	0.00553	CcSEcCtD
Fludrocortisone—Fluid retention—Doxorubicin—sarcoma	0.00251	0.00552	CcSEcCtD
Fludrocortisone—AR—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.0025	0.0178	CbGpPWpGaD
Fludrocortisone—Infection—Dactinomycin—sarcoma	0.0025	0.00549	CcSEcCtD
Fludrocortisone—Vertigo—Vincristine—sarcoma	0.00248	0.00544	CcSEcCtD
Fludrocortisone—Oesophagitis—Doxorubicin—sarcoma	0.00242	0.00532	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Doxorubicin—sarcoma	0.00241	0.00529	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Epirubicin—sarcoma	0.0024	0.00527	CcSEcCtD
Fludrocortisone—Neoplasm—Doxorubicin—sarcoma	0.0024	0.00526	CcSEcCtD
Fludrocortisone—Ecchymosis—Doxorubicin—sarcoma	0.0024	0.00526	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Epirubicin—sarcoma	0.00239	0.00525	CcSEcCtD
Fludrocortisone—Convulsion—Vincristine—sarcoma	0.00239	0.00524	CcSEcCtD
Fludrocortisone—Hypertension—Vincristine—sarcoma	0.00238	0.00523	CcSEcCtD
Fludrocortisone—Myalgia—Vincristine—sarcoma	0.00235	0.00515	CcSEcCtD
Fludrocortisone—Convulsion—Mitoxantrone—sarcoma	0.00233	0.00511	CcSEcCtD
Fludrocortisone—Vascular purpura—Epirubicin—sarcoma	0.00232	0.0051	CcSEcCtD
Fludrocortisone—Hypertension—Mitoxantrone—sarcoma	0.00232	0.00509	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00231	0.00508	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00229	0.00504	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Epirubicin—sarcoma	0.00229	0.00503	CcSEcCtD
Fludrocortisone—Myalgia—Mitoxantrone—sarcoma	0.00229	0.00502	CcSEcCtD
Fludrocortisone—AR—Notch-mediated HES/HEY network—KDR—sarcoma	0.00228	0.0162	CbGpPWpGaD
Fludrocortisone—Anaphylactic shock—Vincristine—sarcoma	0.00225	0.00494	CcSEcCtD
Fludrocortisone—Oedema—Vincristine—sarcoma	0.00225	0.00494	CcSEcCtD
Fludrocortisone—Infection—Vincristine—sarcoma	0.00223	0.00491	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Doxorubicin—sarcoma	0.00222	0.00488	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Doxorubicin—sarcoma	0.00221	0.00485	CcSEcCtD
Fludrocortisone—Oedema—Mitoxantrone—sarcoma	0.00219	0.00481	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Mitoxantrone—sarcoma	0.00219	0.00481	CcSEcCtD
Fludrocortisone—Infection—Mitoxantrone—sarcoma	0.00218	0.00478	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Vincristine—sarcoma	0.00217	0.00478	CcSEcCtD
Fludrocortisone—Purpura—Epirubicin—sarcoma	0.00216	0.00473	CcSEcCtD
Fludrocortisone—Vascular purpura—Doxorubicin—sarcoma	0.00215	0.00472	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Epirubicin—sarcoma	0.00215	0.00472	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Doxorubicin—sarcoma	0.00212	0.00466	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Mitoxantrone—sarcoma	0.00212	0.00465	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Vincristine—sarcoma	0.00205	0.0045	CcSEcCtD
Fludrocortisone—Affect lability—Epirubicin—sarcoma	0.00205	0.00449	CcSEcCtD
Fludrocortisone—Insomnia—Vincristine—sarcoma	0.00203	0.00447	CcSEcCtD
Fludrocortisone—Urticaria—Thiotepa—sarcoma	0.00202	0.00443	CcSEcCtD
Fludrocortisone—Vertigo—Etoposide—sarcoma	0.00201	0.0044	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.002	0.00438	CcSEcCtD
Fludrocortisone—Purpura—Doxorubicin—sarcoma	0.002	0.00438	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Doxorubicin—sarcoma	0.00199	0.00436	CcSEcCtD
Fludrocortisone—Mood swings—Epirubicin—sarcoma	0.00197	0.00432	CcSEcCtD
Fludrocortisone—Convulsion—Etoposide—sarcoma	0.00193	0.00425	CcSEcCtD
Fludrocortisone—Hypertension—Etoposide—sarcoma	0.00193	0.00423	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.0019	0.0135	CbGpPWpGaD
Fludrocortisone—Affect lability—Doxorubicin—sarcoma	0.00189	0.00416	CcSEcCtD
Fludrocortisone—Hypersensitivity—Thiotepa—sarcoma	0.00187	0.0041	CcSEcCtD
Fludrocortisone—Hypersensitivity—Dactinomycin—sarcoma	0.00185	0.00407	CcSEcCtD
Fludrocortisone—Muscular weakness—Epirubicin—sarcoma	0.00183	0.00402	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Etoposide—sarcoma	0.00182	0.004	CcSEcCtD
Fludrocortisone—Mood swings—Doxorubicin—sarcoma	0.00182	0.004	CcSEcCtD
Fludrocortisone—Asthenia—Thiotepa—sarcoma	0.00182	0.004	CcSEcCtD
Fludrocortisone—Infection—Etoposide—sarcoma	0.00181	0.00398	CcSEcCtD
Fludrocortisone—Abdominal distension—Epirubicin—sarcoma	0.00181	0.00397	CcSEcCtD
Fludrocortisone—Asthenia—Dactinomycin—sarcoma	0.00181	0.00397	CcSEcCtD
Fludrocortisone—AR—Nongenotropic Androgen signaling—SRC—sarcoma	0.0018	0.0128	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.00178	0.0127	CbGpPWpGaD
Fludrocortisone—Hyperhidrosis—Etoposide—sarcoma	0.00176	0.00387	CcSEcCtD
Fludrocortisone—Pancreatitis—Epirubicin—sarcoma	0.00176	0.00387	CcSEcCtD
Fludrocortisone—Urticaria—Mitoxantrone—sarcoma	0.00174	0.00382	CcSEcCtD
Fludrocortisone—Muscular weakness—Doxorubicin—sarcoma	0.0017	0.00372	CcSEcCtD
Fludrocortisone—Abdominal distension—Doxorubicin—sarcoma	0.00167	0.00367	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00166	0.0118	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Vincristine—sarcoma	0.00166	0.00364	CcSEcCtD
Fludrocortisone—AR—Androgen receptor signaling pathway—FOXO1—sarcoma	0.00165	0.0117	CbGpPWpGaD
Fludrocortisone—Pancreatitis—Doxorubicin—sarcoma	0.00163	0.00358	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Epirubicin—sarcoma	0.00162	0.00356	CcSEcCtD
Fludrocortisone—Hypersensitivity—Mitoxantrone—sarcoma	0.00161	0.00354	CcSEcCtD
Fludrocortisone—Asthenia—Vincristine—sarcoma	0.00161	0.00354	CcSEcCtD
Fludrocortisone—NR3C1—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.0016	0.0114	CbGpPWpGaD
Fludrocortisone—Headache—Thiotepa—sarcoma	0.00159	0.00349	CcSEcCtD
Fludrocortisone—Asthenia—Mitoxantrone—sarcoma	0.00157	0.00345	CcSEcCtD
Fludrocortisone—AR—FOXA1 transcription factor network—JUN—sarcoma	0.00152	0.0108	CbGpPWpGaD
Fludrocortisone—AR—Regulation of Androgen receptor activity—MDM2—sarcoma	0.0015	0.0107	CbGpPWpGaD
Fludrocortisone—Hyperglycaemia—Doxorubicin—sarcoma	0.0015	0.00329	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—FUS—sarcoma	0.00149	0.0106	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.00145	0.0103	CbGpPWpGaD
Fludrocortisone—Urticaria—Etoposide—sarcoma	0.00145	0.00318	CcSEcCtD
Fludrocortisone—Haemoglobin—Epirubicin—sarcoma	0.00145	0.00317	CcSEcCtD
Fludrocortisone—Haemorrhage—Epirubicin—sarcoma	0.00144	0.00316	CcSEcCtD
Fludrocortisone—Headache—Vincristine—sarcoma	0.00141	0.00309	CcSEcCtD
Fludrocortisone—Headache—Mitoxantrone—sarcoma	0.00137	0.00301	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.00135	0.00961	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Etoposide—sarcoma	0.00134	0.00295	CcSEcCtD
Fludrocortisone—NR3C1—Circadian Clock—CREB1—sarcoma	0.00134	0.0095	CbGpPWpGaD
Fludrocortisone—Haemoglobin—Doxorubicin—sarcoma	0.00134	0.00294	CcSEcCtD
Fludrocortisone—Haemorrhage—Doxorubicin—sarcoma	0.00133	0.00292	CcSEcCtD
Fludrocortisone—Asthenia—Etoposide—sarcoma	0.00131	0.00287	CcSEcCtD
Fludrocortisone—AR—Regulation of Androgen receptor activity—JUN—sarcoma	0.00131	0.00927	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.00129	0.00918	CbGpPWpGaD
Fludrocortisone—AR—Nongenotropic Androgen signaling—HRAS—sarcoma	0.00127	0.00899	CbGpPWpGaD
Fludrocortisone—Erythema—Epirubicin—sarcoma	0.00125	0.00275	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.00122	0.00863	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—CREB1—sarcoma	0.0012	0.00852	CbGpPWpGaD
Fludrocortisone—AR—Regulation of Androgen receptor activity—SRC—sarcoma	0.00117	0.00832	CbGpPWpGaD
Fludrocortisone—AR—Coregulation of Androgen receptor activity—CCND1—sarcoma	0.00117	0.0083	CbGpPWpGaD
Fludrocortisone—AR—Coregulation of Androgen receptor activity—CTNNB1—sarcoma	0.00116	0.00822	CbGpPWpGaD
Fludrocortisone—Erythema—Doxorubicin—sarcoma	0.00116	0.00254	CcSEcCtD
Fludrocortisone—Headache—Etoposide—sarcoma	0.00114	0.00251	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—MDM2—sarcoma	0.00114	0.00809	CbGpPWpGaD
Fludrocortisone—Vertigo—Epirubicin—sarcoma	0.00112	0.00247	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CREB1—sarcoma	0.0011	0.00783	CbGpPWpGaD
Fludrocortisone—Convulsion—Epirubicin—sarcoma	0.00108	0.00238	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.00108	0.00769	CbGpPWpGaD
Fludrocortisone—Hypertension—Epirubicin—sarcoma	0.00108	0.00237	CcSEcCtD
Fludrocortisone—Myalgia—Epirubicin—sarcoma	0.00107	0.00234	CcSEcCtD
Fludrocortisone—Vertigo—Doxorubicin—sarcoma	0.00104	0.00228	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Epirubicin—sarcoma	0.00102	0.00224	CcSEcCtD
Fludrocortisone—Oedema—Epirubicin—sarcoma	0.00102	0.00224	CcSEcCtD
Fludrocortisone—Infection—Epirubicin—sarcoma	0.00101	0.00223	CcSEcCtD
Fludrocortisone—Convulsion—Doxorubicin—sarcoma	0.001	0.0022	CcSEcCtD
Fludrocortisone—Hypertension—Doxorubicin—sarcoma	0.001	0.0022	CcSEcCtD
Fludrocortisone—AR—Androgen receptor signaling pathway—MDM2—sarcoma	0.000993	0.00705	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—JUN—sarcoma	0.000991	0.00703	CbGpPWpGaD
Fludrocortisone—Hyperhidrosis—Epirubicin—sarcoma	0.000987	0.00217	CcSEcCtD
Fludrocortisone—Myalgia—Doxorubicin—sarcoma	0.000986	0.00216	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000982	0.00697	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—CREB1—sarcoma	0.000972	0.0069	CbGpPWpGaD
Fludrocortisone—Oedema—Doxorubicin—sarcoma	0.000945	0.00208	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Doxorubicin—sarcoma	0.000945	0.00208	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000942	0.00668	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.00094	0.00667	CbGpPWpGaD
Fludrocortisone—Infection—Doxorubicin—sarcoma	0.000939	0.00206	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000933	0.00662	CbGpPWpGaD
Fludrocortisone—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000931	0.00204	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.00093	0.0066	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—FOXO1—sarcoma	0.000927	0.00658	CbGpPWpGaD
Fludrocortisone—Insomnia—Epirubicin—sarcoma	0.000924	0.00203	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Doxorubicin—sarcoma	0.000914	0.00201	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—SRC—sarcoma	0.000889	0.00631	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000883	0.00626	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—CCND1—sarcoma	0.000865	0.00614	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—JUN—sarcoma	0.000863	0.00612	CbGpPWpGaD
Fludrocortisone—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000861	0.00189	CcSEcCtD
Fludrocortisone—AR—Androgen receptor signaling pathway—CTNNB1—sarcoma	0.000856	0.00608	CbGpPWpGaD
Fludrocortisone—Insomnia—Doxorubicin—sarcoma	0.000855	0.00188	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—IL2—sarcoma	0.000816	0.00579	CbGpPWpGaD
Fludrocortisone—Urticaria—Epirubicin—sarcoma	0.000811	0.00178	CcSEcCtD
Fludrocortisone—NR3C1—Endoderm Differentiation—CTNNB1—sarcoma	0.000806	0.00572	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—sarcoma	0.000804	0.00571	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CCND1—sarcoma	0.000795	0.00564	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—JUN—sarcoma	0.000793	0.00563	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CTNNB1—sarcoma	0.000787	0.00559	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000786	0.00558	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—SRC—sarcoma	0.000774	0.00549	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000766	0.00544	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.000755	0.00536	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Epirubicin—sarcoma	0.000753	0.00165	CcSEcCtD
Fludrocortisone—Urticaria—Doxorubicin—sarcoma	0.000751	0.00165	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	0.000748	0.00531	CbGpPWpGaD
Fludrocortisone—Asthenia—Epirubicin—sarcoma	0.000733	0.00161	CcSEcCtD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—IL2—sarcoma	0.000719	0.0051	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.000706	0.00501	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—JUN—sarcoma	0.000699	0.00496	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Doxorubicin—sarcoma	0.000696	0.00153	CcSEcCtD
Fludrocortisone—AR—Gene Expression—FUS—sarcoma	0.000693	0.00492	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—EGFR—sarcoma	0.000678	0.00482	CbGpPWpGaD
Fludrocortisone—Asthenia—Doxorubicin—sarcoma	0.000678	0.00149	CcSEcCtD
Fludrocortisone—NR3C1—Adipogenesis—CREB1—sarcoma	0.000672	0.00477	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000651	0.00462	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.00065	0.00462	CbGpPWpGaD
Fludrocortisone—Headache—Epirubicin—sarcoma	0.00064	0.00141	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—MYC—sarcoma	0.000638	0.00453	CbGpPWpGaD
Fludrocortisone—Headache—Doxorubicin—sarcoma	0.000592	0.0013	CcSEcCtD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000581	0.00412	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	0.000567	0.00403	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000567	0.00402	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000565	0.00401	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000561	0.00398	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—JUN—sarcoma	0.000551	0.00391	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000547	0.00388	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000539	0.00383	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—FUS—sarcoma	0.000525	0.00373	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—TP53—sarcoma	0.000524	0.00372	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000494	0.00351	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000481	0.00342	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—CTNNB1—sarcoma	0.00048	0.00341	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000469	0.00333	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000468	0.00332	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000465	0.0033	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—TP53—sarcoma	0.000461	0.00327	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000454	0.00323	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000444	0.00315	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.00042	0.00298	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.00042	0.00298	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—JUN—sarcoma	0.000418	0.00297	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000415	0.00294	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000409	0.0029	CbGpPWpGaD
Fludrocortisone—NR3C2—Generic Transcription Pathway—MYC—sarcoma	0.000403	0.00286	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000377	0.00267	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000373	0.00265	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000368	0.00261	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000365	0.00259	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000348	0.00247	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000309	0.00219	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—MYC—sarcoma	0.000194	0.00138	CbGpPWpGaD
Fludrocortisone—AR—Generic Transcription Pathway—MYC—sarcoma	0.000187	0.00133	CbGpPWpGaD
Fludrocortisone—NR3C1—Generic Transcription Pathway—MYC—sarcoma	0.000142	0.00101	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—MYC—sarcoma	9.01e-05	0.000639	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—MYC—sarcoma	6.83e-05	0.000485	CbGpPWpGaD
